DK3893924T3 - Antistoffer til human komplementfaktor C2B og anvendelsesfremgangsmåder - Google Patents
Antistoffer til human komplementfaktor C2B og anvendelsesfremgangsmåder Download PDFInfo
- Publication number
- DK3893924T3 DK3893924T3 DK19832737.1T DK19832737T DK3893924T3 DK 3893924 T3 DK3893924 T3 DK 3893924T3 DK 19832737 T DK19832737 T DK 19832737T DK 3893924 T3 DK3893924 T3 DK 3893924T3
- Authority
- DK
- Denmark
- Prior art keywords
- antibodies
- methods
- complement factor
- human complement
- human
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Transplantation (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Devices For Post-Treatments, Processing, Supply, Discharge, And Other Processes (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862779102P | 2018-12-13 | 2018-12-13 | |
| PCT/IB2019/060802 WO2020121282A1 (en) | 2018-12-13 | 2019-12-13 | Antibodies to human complement factor c2b and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3893924T3 true DK3893924T3 (da) | 2024-11-04 |
Family
ID=69143627
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK19832737.1T DK3893924T3 (da) | 2018-12-13 | 2019-12-13 | Antistoffer til human komplementfaktor C2B og anvendelsesfremgangsmåder |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US11161900B2 (https=) |
| EP (2) | EP4375297A3 (https=) |
| JP (3) | JP7110491B2 (https=) |
| KR (2) | KR102774146B1 (https=) |
| CN (2) | CN119371526A (https=) |
| AU (3) | AU2019397614B2 (https=) |
| BR (1) | BR112021011107A2 (https=) |
| CA (1) | CA3119655A1 (https=) |
| DK (1) | DK3893924T3 (https=) |
| EA (1) | EA202191658A1 (https=) |
| ES (1) | ES2991894T3 (https=) |
| FI (1) | FI3893924T3 (https=) |
| HU (1) | HUE068993T2 (https=) |
| IL (2) | IL319975A (https=) |
| LT (1) | LT3893924T (https=) |
| MX (2) | MX2021006864A (https=) |
| PL (1) | PL3893924T3 (https=) |
| PT (1) | PT3893924T (https=) |
| SG (1) | SG11202105195PA (https=) |
| WO (1) | WO2020121282A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020121282A1 (en) * | 2018-12-13 | 2020-06-18 | Argenx Bvba | Antibodies to human complement factor c2b and methods of use |
| GB2584105B (en) * | 2019-05-21 | 2023-08-02 | Argenx Bvba | Methods of treating neuropathy |
| GB202407051D0 (en) | 2024-05-17 | 2024-07-03 | argenx BV | Methods of treating osteoarthritis pain |
| WO2025257157A1 (en) | 2024-06-10 | 2025-12-18 | argenx BV | Treatment or prevention of ischemia reperfusion injury in organ tranplantation |
| WO2025260123A1 (en) * | 2024-06-17 | 2025-12-26 | CSL Innovation Pty Ltd | Anti-c2 antibodies and uses thereof |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001249410A1 (en) | 2000-03-23 | 2001-10-03 | Tanox, Inc. | Anti-c2/c2a inhibitors of complement activation |
| US8501705B2 (en) | 2003-09-11 | 2013-08-06 | The Board Of Regents Of The University Of Texas System | Methods and materials for treating autoimmune and/or complement mediated diseases and conditions |
| WO2006130834A2 (en) | 2005-05-31 | 2006-12-07 | Board Of Regents, The University Of Texas System | IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF |
| US9399061B2 (en) | 2006-04-10 | 2016-07-26 | Abbvie Biotechnology Ltd | Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis |
| WO2007146968A2 (en) | 2006-06-12 | 2007-12-21 | Trubion Pharmaceuticals, Inc. | Single-chain multivalent binding proteins with effector function |
| LT3028716T (lt) | 2006-10-10 | 2020-12-10 | Regenesance B.V. | Komplemento slopinimas nervų regeneracijos pagerinimui |
| SG10201608871XA (en) | 2008-05-05 | 2016-12-29 | Novimmune Sa | Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof |
| AR072999A1 (es) * | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| WO2010056399A1 (en) | 2008-11-17 | 2010-05-20 | Incode Biopharmaceutics, Inc. | Method and composition for modulating the immune system and various inflammatory conditions comprising complement depletors |
| US9815890B2 (en) * | 2010-06-22 | 2017-11-14 | The Regents Of The University Of Colorado, A Body Corporate | Antibodies to the C3d fragment of complement component 3 |
| CN105968209B (zh) * | 2011-04-19 | 2021-08-03 | 美国政府(由卫生和人类服务部的部长所代表) | 对磷脂酰肌醇蛋白聚糖3特异的人单克隆抗体及其用途 |
| EP2704743B1 (en) * | 2011-05-04 | 2020-03-11 | Omeros Corporation | Compositions for inhibiting masp-2 dependent complement acitivation |
| CN110229216B (zh) | 2011-09-07 | 2023-06-16 | 宾夕法尼亚州大学理事会 | 具有改善的药代动力学性质的坎普他汀类肽 |
| DK2914291T3 (da) * | 2012-11-02 | 2022-05-16 | Bioverativ Usa Inc | Anti-komplement-c1s-antistoffer og anvendelser deraf |
| WO2014096958A1 (en) | 2012-11-02 | 2014-06-26 | Academisch Medisch Centrum | Inosine monophosphate and salts thereof for use in the treatment of complement-related disorders |
| EP2996722A4 (en) | 2013-05-15 | 2017-01-11 | Annexon, Inc. | Methods of treatment for guillain-barre syndrome |
| CN105492461B (zh) | 2013-05-23 | 2019-11-26 | 布罗泰欧制药有限公司 | 结合人类补体因子c2的结合分子及其应用 |
| CA2859114A1 (en) | 2013-08-29 | 2015-02-28 | International Automotive Components Group North America, Inc. | Formed articles comprising carbon and natural fibers, methods of manufacture and use thereof |
| EP3733244A1 (en) | 2013-10-02 | 2020-11-04 | Medlmmune, LLC | Neutralizing anti-influenza a antibodies and uses thereof |
| SMT202000659T1 (it) * | 2013-10-17 | 2021-01-05 | Omeros Corp | Metodi per il trattamento delle condizioni associate all'attivazione del complemento dipendente dalla masp-2 |
| SG10201804960RA (en) | 2013-12-12 | 2018-07-30 | Alnylam Pharmaceuticals Inc | Complement component irna compositions and methods of use thereof |
| HUE070383T2 (hu) | 2014-11-05 | 2025-06-28 | Annexon Inc | Humanizált C1Q anti-komplement faktor antitestek és alkalmazásaik |
| MX2018006249A (es) | 2015-11-19 | 2018-11-09 | Abbvie Stemcentrx Llc | Nuevos anticuerpos anti-emr2 y metodos de uso. |
| WO2017091719A1 (en) | 2015-11-24 | 2017-06-01 | Annexon, Inc. | Anti-complement factor c1q fab fragments and uses thereof |
| EP3408291A1 (en) | 2016-01-25 | 2018-12-05 | Shire Human Genetic Therapies, Inc. | Anti-c5 antibodies with enhanced ph switch |
| EP3408279A1 (en) | 2016-01-27 | 2018-12-05 | CSL Behring Lengnau AG | Recombinant igg fc multimers |
| EP3454902A4 (en) | 2016-05-10 | 2019-10-09 | Annexon, Inc. | ANTI-COMPLEMENT FACTOR C4 / C4B ANTIBODIES AND USES THEREOF |
| WO2018107109A1 (en) | 2016-12-09 | 2018-06-14 | Abbvie Stemcentrx Llc | Novel anti-kremen2 antibodies and methods of use |
| CA3055781A1 (en) | 2017-03-14 | 2018-09-20 | Bioverativ Usa Inc. | Methods for treating complement-mediated diseases and disorders |
| JP2020517242A (ja) | 2017-04-21 | 2020-06-18 | スターテン・バイオテクノロジー・ベー・フェー | 抗ＡｐｏＣ３抗体およびその使用方法 |
| AU2018360697A1 (en) | 2017-11-01 | 2020-05-14 | Alnylam Pharmaceuticals, Inc. | Complement component C3 iRNA compositions and methods of use thereof |
| WO2020121282A1 (en) | 2018-12-13 | 2020-06-18 | Argenx Bvba | Antibodies to human complement factor c2b and methods of use |
| GB2584105B (en) * | 2019-05-21 | 2023-08-02 | Argenx Bvba | Methods of treating neuropathy |
-
2019
- 2019-12-13 WO PCT/IB2019/060802 patent/WO2020121282A1/en not_active Ceased
- 2019-12-13 SG SG11202105195PA patent/SG11202105195PA/en unknown
- 2019-12-13 LT LTEPPCT/IB2019/060802T patent/LT3893924T/lt unknown
- 2019-12-13 PT PT198327371T patent/PT3893924T/pt unknown
- 2019-12-13 CN CN202411410387.8A patent/CN119371526A/zh active Pending
- 2019-12-13 AU AU2019397614A patent/AU2019397614B2/en active Active
- 2019-12-13 MX MX2021006864A patent/MX2021006864A/es unknown
- 2019-12-13 FI FIEP19832737.1T patent/FI3893924T3/fi active
- 2019-12-13 IL IL319975A patent/IL319975A/en unknown
- 2019-12-13 JP JP2021533300A patent/JP7110491B2/ja active Active
- 2019-12-13 IL IL283916A patent/IL283916B2/en unknown
- 2019-12-13 HU HUE19832737A patent/HUE068993T2/hu unknown
- 2019-12-13 DK DK19832737.1T patent/DK3893924T3/da active
- 2019-12-13 BR BR112021011107A patent/BR112021011107A2/pt unknown
- 2019-12-13 EP EP24164880.7A patent/EP4375297A3/en active Pending
- 2019-12-13 PL PL19832737.1T patent/PL3893924T3/pl unknown
- 2019-12-13 EP EP19832737.1A patent/EP3893924B1/en active Active
- 2019-12-13 CA CA3119655A patent/CA3119655A1/en active Pending
- 2019-12-13 EA EA202191658A patent/EA202191658A1/ru unknown
- 2019-12-13 US US16/714,264 patent/US11161900B2/en active Active
- 2019-12-13 KR KR1020217021353A patent/KR102774146B1/ko active Active
- 2019-12-13 ES ES19832737T patent/ES2991894T3/es active Active
- 2019-12-13 KR KR1020257005663A patent/KR20250030005A/ko active Pending
- 2019-12-13 CN CN201980082826.8A patent/CN113260375B/zh active Active
-
2021
- 2021-06-10 MX MX2025010337A patent/MX2025010337A/es unknown
- 2021-10-01 US US17/491,656 patent/US11591386B2/en active Active
-
2022
- 2022-01-10 US US17/572,518 patent/US11708403B2/en active Active
- 2022-07-20 JP JP2022115252A patent/JP7611191B2/ja active Active
- 2022-12-15 AU AU2022287637A patent/AU2022287637B2/en active Active
-
2023
- 2023-06-07 US US18/330,903 patent/US20240002484A1/en active Pending
-
2024
- 2024-08-01 JP JP2024125608A patent/JP2024160274A/ja active Pending
-
2025
- 2025-10-17 AU AU2025252632A patent/AU2025252632A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL281683A (en) | Dll3 binding proteins and methods of use | |
| DK3618928T5 (da) | Anti-Sortilin-antistoffer og fremgangsmåder til anvendelse deraf | |
| DK3601358T3 (da) | Anti-trem2-antistoffer og fremgangsmåder til anvendelse deraf | |
| DK3618863T3 (da) | Anti-tigit-antistoffer og fremgangsmåder til anvendelse deraf | |
| DK3515478T3 (da) | Antistoffer til SIGLEC-15 og fremgangsmåder til anvendelse deraf | |
| DK4186920T5 (da) | Ultra-langtidsvirkende insulin-fc-fusionsproteiner og fremgangsmåder til anvendelse | |
| DK3774789T3 (da) | BRM-målrettede forbindelser og tilhørende fremgangsmåder til anvendelse | |
| DK3707159T5 (da) | Hidtil ukendte modificerede t-cellereceptorer og immunterapi med anvendelse deraf | |
| DK3694529T3 (da) | Trispecifikke proteiner og anvendelsesfremgangsmåder | |
| DK4190355T3 (da) | Formuleringer af humane anti-rankl-antistoffer og fremgangsmåder til anvendelse deraf | |
| DK3661954T3 (da) | Interleukin-21-muteiner og fremgangsmåder til behandling | |
| DK3893924T3 (da) | Antistoffer til human komplementfaktor C2B og anvendelsesfremgangsmåder | |
| DK3788044T3 (da) | RIP1-hæmmende forbindelser og fremgangsmåder til fremstilling og anvendelse heraf | |
| DK3525583T3 (da) | Anti-c1s-antistoffer og fremgangsmåder til anvendelse deraf | |
| DK3551660T5 (da) | Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf | |
| DK3436048T3 (da) | Neoantigener og fremgangsmåder til anvendelse deraf | |
| DK3353210T3 (da) | Anti-TIGIT-antistoffer og fremgangsmåder til anvendelse | |
| DK3653221T5 (da) | Anti-pvrig-antistoffer og anvendelsesfremgangsmåder | |
| DK3478723T3 (da) | Pd l1 specifikke antistoffer og metoder til anvendelse heraf | |
| IL254670A0 (en) | Humanized anti-c1s antibodies and methods of use thereof | |
| IL285401A (en) | Anti-clec2d antibodies and methods of use thereof | |
| DK3565579T3 (da) | Pd1-41bbl-fusionsprotein og fremgangsmåder til anvendelse deraf | |
| DK3743447T3 (da) | B7-H4-antistoffer og fremgangsmåder til anvendelse deraf | |
| IL283782A (en) | Anellosomes and methods of use | |
| DK4073098T3 (da) | Ultralangtidsvirkende insulin-Fc-fusionsproteiner og fremgangsmåder til anvendelse |